WO2005011645A3 - Selected betaines and their uses - Google Patents

Selected betaines and their uses Download PDF

Info

Publication number
WO2005011645A3
WO2005011645A3 PCT/BE2004/000110 BE2004000110W WO2005011645A3 WO 2005011645 A3 WO2005011645 A3 WO 2005011645A3 BE 2004000110 W BE2004000110 W BE 2004000110W WO 2005011645 A3 WO2005011645 A3 WO 2005011645A3
Authority
WO
WIPO (PCT)
Prior art keywords
physiologically acceptable
betaines
betaine
selected betaines
pyrogen
Prior art date
Application number
PCT/BE2004/000110
Other languages
French (fr)
Other versions
WO2005011645A8 (en
WO2005011645A2 (en
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/635,048 external-priority patent/US7608640B2/en
Application filed by Jallal Messadek filed Critical Jallal Messadek
Priority to CA002575760A priority Critical patent/CA2575760A1/en
Priority to EP04761471A priority patent/EP1660070A2/en
Publication of WO2005011645A2 publication Critical patent/WO2005011645A2/en
Publication of WO2005011645A3 publication Critical patent/WO2005011645A3/en
Priority to US11/348,142 priority patent/US20060128657A1/en
Publication of WO2005011645A8 publication Critical patent/WO2005011645A8/en
Priority to US12/510,034 priority patent/US20090286881A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500mg/ml.
PCT/BE2004/000110 2003-08-04 2004-08-03 Selected betaines and their uses WO2005011645A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002575760A CA2575760A1 (en) 2003-08-04 2004-08-03 Selected betaines and their uses
EP04761471A EP1660070A2 (en) 2003-08-04 2004-08-03 Selected betaines and their uses
US11/348,142 US20060128657A1 (en) 2003-08-04 2006-02-06 Selected betaines and their uses
US12/510,034 US20090286881A1 (en) 2003-08-04 2009-07-27 Selected betaines and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/635,048 US7608640B2 (en) 1999-03-02 2003-08-04 Glycine betaine and its use
US10/635,048 2003-08-04
BEPCT/BE04/00043 2004-03-23
BEPCT/BE04/000043 2004-03-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
BEPCT/BE04/00043 Continuation-In-Part 2003-08-04 2004-03-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/635,048 Continuation-In-Part US7608640B2 (en) 1999-03-02 2003-08-04 Glycine betaine and its use
US11/348,142 Continuation-In-Part US20060128657A1 (en) 2003-08-04 2006-02-06 Selected betaines and their uses

Publications (3)

Publication Number Publication Date
WO2005011645A2 WO2005011645A2 (en) 2005-02-10
WO2005011645A3 true WO2005011645A3 (en) 2005-04-14
WO2005011645A8 WO2005011645A8 (en) 2006-05-11

Family

ID=37594137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2004/000110 WO2005011645A2 (en) 2003-08-04 2004-08-03 Selected betaines and their uses

Country Status (2)

Country Link
CA (1) CA2575760A1 (en)
WO (1) WO2005011645A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
CA2650556A1 (en) 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065320A1 (en) * 1999-03-02 2002-05-30 Jallal Messadek Glycine betaine and its use
WO2002062322A2 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065320A1 (en) * 1999-03-02 2002-05-30 Jallal Messadek Glycine betaine and its use
WO2002062322A2 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent

Also Published As

Publication number Publication date
WO2005011645A8 (en) 2006-05-11
CA2575760A1 (en) 2005-02-10
WO2005011645A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2004007679A3 (en) Dendritic cell pontentiation
NZ533179A (en) Hydroxycucurbituril derivatives, their preparation methods and uses
TW200506064A (en) Method for concealing a secret information carried within a DNA molecule and method for decoding a secret information that have been concealed by said concealing method
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
EP1551834A4 (en) Substituted quinazolinone compounds
WO2007128817A3 (en) Insulin derivative
WO2007106554A3 (en) Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
WO2003022208A3 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP2172246A3 (en) Methods for Alzheimer's disease treatment and cognitive enhancement
WO2005115416A3 (en) Method of treating with chlorine dioxide
WO2003101919A3 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
IS7491A (en) Benzoxazinone-derived compounds, their preparation and use as drugs
WO2005011645A8 (en) Selected betaines and their uses
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
ATE366106T1 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE TO COMBAT HAIR LOSS
WO2006041409A8 (en) Medical solution, method for producing and use thereof
UA83737C2 (en) Method for reducing the cyanide levels in a mesotrione sample
WO2003089458A3 (en) Conjugates of membrane translocating agents and pharmaceutically active agents
WO2007072018A3 (en) Redox mediators
DK2185561T3 (en) Derivatives of 1,2,3,4-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamide and 2,3,4,5-tetrahydroprrolo (1,2-a) -diazepine-7-carboxamide, preparation thereof and therapeutic use thereof
UA83888C2 (en) Pharmaceutical composition of vinflunine for parenteral administration, preparation method thereof and use of same
WO2005040283A3 (en) Disperse azo dyestuffs
WO2005001042A3 (en) Smooth muscle progenitor cells
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11348142

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004761471

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 06/2005 UNDER (30) REPLACE "2004/033223" BY "10/635,048"

WWP Wipo information: published in national office

Ref document number: 2004761471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11348142

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2575760

Country of ref document: CA